In a presentation at the 2022 NORD Breakthrough Summit, FDA Commissioner Robert M. Califf highlighted the significance of Real World Data (RWD) and Real World Evidence in enhancing clinical research, particularly for rare diseases and oncology. The primary challenge with RWD lies in the need to preserve patient privacy while enabling data sharing and analysis. To address this, Duality Technologies has developed a toolset utilizing fully homomorphic encryption (FHE) for secure data analysis, allowing computation on encrypted data without revealing raw data. In collaboration with Tel Aviv Sourasky Medical Center and Dana Farber Cancer Institute, this toolset was applied to oncological data, including a study on colorectal cancer patients, demonstrating its efficacy in performing statistical analyses with high accuracy and significantly reduced runtime compared to traditional methods. This advancement in privacy-preserving technology is seen as a pivotal development for collaborative research, allowing for comprehensive data analysis while ensuring data privacy, and a paper detailing these findings has been submitted to a prestigious journal for publication.